SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Oncology Pharmacy Practice
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Paris, I.
Right arrow Articles by Bourget, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paris, I.
Right arrow Articles by Bourget, P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Microbial growth tests in anti-neoplastic injectable solutions

Isabelle Paris, Resident

Department of Clinical Pharmacy, Institut Gustave-Roussy, Villejuif, France

Angelo Paci, PharmD, PhD

Department of Clinical Pharmacy, Institut Gustave-Roussy, Villejuif, France

Jean-Baptiste Rey, PharmD

Department of Clinical Pharmacy, Institut Gustave-Roussy, Villejuif, France

Philippe Bourget, PharmD, PhD

Department of Clinical Pharmacy, Institut Gustave-Roussy, Villejuif, France

The Institut Gustave-Roussy (IGR) Department of Clinical Pharmacy (DCP) ensures the annual preparation of about 30 000 therapeutic batches of anti-neoplastic agents.High performance thin-layer chromatography (HPTLC) allows postproduction quality control of these batches.Although the centralized chemotherapy manufacturing unit has been recently ISO 9001:2000 certified, it was considered to improve the quality level of manufactured batches even further.The viability of micro-organisms (bacteria and fungi) in appropriate sterile media containing various anti-neoplastic agents at therapeutic concentration was assessed to demonstrate the lack of contamination during our manufacturing process in the isolator.After 14 days of incubation in these media, the results show the absence of contamination of the manufactured batches.This leads us to conclude that using sterile drugs and sterile medical devices in a sterile isolator allows the manufacture of sterile therapeutic batches with excellent confidence.

Key Words: chemotherapy • clinical pharmacy • quality assurance • quality control • sterility

Journal of Oncology Pharmacy Practice, Vol. 11, No. 1, 7-12 (2005)
DOI: 10.1191/1078155205jp143oa
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J Oncol Pharm PractHome page
S. Kaestner and G. Sewell
Dose-banding of carboplatin: rationale and proposed banding scheme
Journal of Oncology Pharmacy Practice, June 1, 2007; 13(2): 109 - 117.
[Abstract] [PDF]


Advertisement